Talk about the views after Chi-Med authorized fruquintinib to Takeda Pharmaceutical
Disclaimer: This article is only a record of personal investment thinking and does not constitute investment advice. Chi-Med is a target that I have always adhered to, and it is also a target that I am very optimistic about. Chi-Med announced on January 23, 2023 that Chi-Med announced that its subsidiary Hutchison Whampoa Pharmaceuticals (Shanghai) […]
Talk about the views after Chi-Med authorized fruquintinib to Takeda Pharmaceutical Read More »